Skip to main content

Paulo Limjenco

Vice President of Business Operations at YPrime and ESG Strategy Lead focused on sustainability in clinical trials.

Jun 15, 2026

7:43
How do you think about this, Paulo, when we're thinking about those bigger impacts?
7:48
I think with the industry a- as a whole, there is a common theme of efficiency.
7:53
And then I guess a, a common example from our organization at Y Prime is the introduction of, um, an AI-backed and powered migration process.
8:02
So we actually found that it ...
8:03
From, from our perspective, the ability to introduce efficiency through faster approvals, through cleaner data, more inclusive, the conducting of trials in general, is part of how we define that concept.
8:16
So having the ability in, in our case, to reduce the number of, um, screen reports, um, containing errors, just a better quality screen reports, uh, or reduction in human-led migration errors for the localization process, it really had the ability to shorten our entire review process by over 60%.
8:37
So there were actually, in addition to that, no additional error types introduced as part of that review.

23 MINS LATER

32:03
Paulo, what are your thoughts?

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.